

BMB Reports – Manuscript Submission

Manuscript Draft

Manuscript Number: BMB-16-080

Title: Mycobacterium abscessus D-alanyl-D-alanine dipeptidase induces the maturation of dendritic cells and promotes Th1-biased immunity

Article Type: Article

Keywords: Dendritic cells; Th1 polarization; TLR4; Mycobacterium abscessus; MAB1843

Corresponding Author: Yeong-Min Park

Authors: Seung Jun Lee¹, Jong-Hwa Jang², Gun Young Yun¹, Da Rae Kang¹, Hee Jo Park¹, Sung Jae Shin³, Hee Dong Han¹, Tae Heung Kang¹, Won Sun Park⁴, Young Kyung Yoon⁵, In Duk Jung¹, Yeong-Min Park^{1,*}

Institution: ¹Department of Immunology, Konkuk University,

²Department of Dental Hygiene, Hanseo University,

³Department of Microbiology, Yonsei University College of Medicine,

⁴Department of Physiology, Kangwon National University,

⁵Division of Infectious Diseases, Korea University,

1 ***Mycobacterium abscessus* D-alanyl-D-alanine dipeptidase induces the maturation of**
2 **dendritic cells and promotes Th1-biased immunity**

3 Seung Jun Lee^{1,*}, Jong-Hwa Jang^{2,*}, Gun Young Yun¹, Da Rae Kang¹, Hee Jo Park¹, Sung Jae
4 Shin³, Hee Dong Han¹, Tae Heung Kang¹, Won Sun Park⁴, Young Kyung Yoon⁵, In Duk
5 Jung^{1,**}, Yeong-Min Park^{1,**}

6 ¹ *Department of Immunology, Laboratory of Dendritic Cell Differentiation and Regulation,*
7 *School of Medicine, Konkuk University, Chungju 380-701, Republic of Korea*

8 ² *Department of Dental Hygiene, Hanseo University, Seosan 356-706, Republic of Korea*

9 ³ *Department of Microbiology, Institute for Immunology and Immunological Diseases, Brain*
10 *Korea 21 PLUS Project for Medical Science, Yonsei University College of Medicine, Seoul*
11 *120-752, Republic of Korea*

12 ⁴ *Department of Physiology, School of Medicine, Kangwon National University, Chuncheon*
13 *200-701, Republic of Korea*

14 ⁵ *Division of Infectious Diseases, Department of Internal Medicine, Korea University Anam*
15 *Hospital, College of Medicine, Korea University, Seoul, Republic of Korea*

16

17 **Running Title:** MAB1843 activates the functions of dendritic cells

18 ******Corresponding author: In Duk Jung, Ph.D. & Yeong-Min Park, M.D., Ph.D. Department of
19 Immunology, Laboratory of Dendritic Cell Differentiation & Regulation, School of Medicine,
20 Konkuk University, Chungju 380-701, Republic of Korea. Phone: +82-2-2049-6330; Fax:
21 +82-2-2049-6192; E-mail: jungid@kku.ac.kr & immun3023@kku.ac.kr.

22 *****These authors contributed equally to this work.

23

1 **ABSTRACT**

2 *Mycobacterium abscessus*, a member of the group of non-tuberculous mycobacteria,
3 has been identified as an emerging pulmonary pathogen in humans. However, little is known
4 about the protective immune response of antigen-presenting cells, such as dendritic cells
5 (DCs), which guard against *M. abscessus* infection. The *M. abscessus* gene *MAB1843*
6 encodes D-alanyl-D-alanine dipeptidase, which catalyzes the hydrolysis of D-alanyl-D-alanine
7 dipeptide. We investigated whether MAB1843 is able to interact with DCs to enhance the
8 effectiveness of the host's immune response. MAB1843 was found to induce DC maturation
9 via toll-like receptor 4 and its downstream signaling pathways, such as the mitogen-activated
10 protein kinase and nuclear factor kappa B pathways. In addition, MAB1843-treated DCs
11 stimulated the proliferation of T cells and promoted Th1 polarization. Our results indicate that
12 MAB1843 could potentially regulate the immune response to *M. abscessus*, making it
13 important in the development of an effective vaccine against this mycobacterium.

14

15 **Keywords:** Dendritic cells, Th1 polarization, MAPK, *Mycobacterium abscessus*, MAB1843

16

17

18

19

20

21

22

23

24

1 INTRODUCTION

2 *Mycobacterium abscessus* is the most well known rapidly growing mycobacterium
3 (RGM), existing in natural habitats such as soil and water (1, 2) and usually found in
4 intracellular compartments within an infected host. Infection by this mycobacterium can
5 occur in various parts of the host's body, regardless of their immunity. Approximately 80% of
6 pulmonary RGM infections in the USA are attributed to *M. abscessus* (3). Unfortunately, the
7 resistance of this species to antituberculosis drugs and antibiotics has become a major
8 obstacle to its treatment in infected patients (4-6).

9 Recent studies have revealed that antigen-presenting cell (APC)-mediated innate and
10 adaptive immunities play a pivotal role in combating *M. abscessus* infection (7-9). These
11 studies also pointed out the importance of research on the pathogenicity of *M. abscessus* and
12 relevant immunotherapies. In the *M. abscessus*-infected mouse model, the interferon-gamma
13 (IFN- γ) and tumor necrosis factor alpha (TNF- α) secreted by various immune cells play a key
14 role as regulators of the bacterial infection (10, 11). Furthermore, *M. abscessus* induces
15 dendritic cell (DC) and macrophage secretion of TNF- α , interleukin-6 (IL-6), and IL-12p70
16 via the toll-like receptor 2 (TLR2) and TLR4 pathways (7, 8).

17 DCs are well known as the most powerful APCs. In peripheral tissues, immature DCs
18 express low levels of costimulatory and major histocompatibility complex (MHC) molecules
19 and exhibit a high level of endocytosis (12, 13). When DCs recognize pathogens via pattern
20 recognition receptors, they start maturing, and in the process express high levels of
21 costimulatory and MHC molecules, and proinflammatory cytokines, and their endocytosis
22 capacity is downregulated. In addition, DC maturation occurs as the cells migrate towards the
23 lymph nodes where they present antigens to naïve T cells, which induces T cell activation and
24 proliferation. In this way, DCs act as the link between innate immunity and adaptive

1 immunity, and hence, they have gained much attention in cancer immunotherapy research
2 (12-15).

3 Mycobacterial proteins, such as PE-RGRS, LprA, MAB2560, Rv0652, Rv0462,
4 MAP1305, HspX, and HBHA, have been shown to induce DC maturation and T cell
5 activation (8, 16-22). These proteins activate TLR2 or TLR4 signaling and can be used as
6 adjuvants for DC maturation. We recently suggested MAB2560 as the first ligand isolated
7 from *M. abscessus* that induces the activation of DCs via TLR4; however, little is known
8 about how *M. abscessus*-derived ligands affect the immune system.

9 MAB1843, a 222-amino-acid D-alanyl-D-alanine dipeptidase (D-Ala-D-Ala
10 dipeptidase; EC number: 3.4.13.22), is a hypothetical antigen of *M. abscessus*. However, the
11 function of MAB1843 in *M. abscessus* and the manner in which it affects the immune system
12 remain unknown.

13 In this study, we aimed to elucidate the effects of MAB1843 on the immune system,
14 with a focus on the maturation of DCs as well as their endocytosis and cytokine-producing
15 abilities. In particular, we examined whether MAB1843 affects DC maturation through TLRs
16 and how the activated DCs affect T cells. Knowledge on these mechanisms could contribute
17 to the development of vaccines against *M. abscessus*.

1 RESULTS

2 MAB1843 Induces Dendritic Cell Maturation

3 First, we inspected the purity and toxicity of the recombinant MAB1843 before
4 testing its physiological effect on DCs. The purity of MAB1843 was confirmed by
5 Coomassie Brilliant Blue staining and western blot analysis using anti-His antibody (Ab).
6 The apparent molecular size of the purified protein was approximately 24 kDa (Fig. 1A). In
7 addition, the toxicity of MAB1843 on DCs was tested using Annexin V/propidium iodide (PI)
8 staining and analyzed by fluorescence-activated cell sorting. Compared with the effect of a
9 high dose of lipopolysaccharide (LPS; 1000 ng/mL) as a positive control, MAB1843 was not
10 cytotoxic to DCs (Fig. 1B). To exclude the effects of endotoxin contamination, we also
11 checked for endotoxins in the purified MAB1843. Using the limulus amoebocyte lysate (LAL)
12 endotoxin assay kit (Lonza, Basel, Switzerland), we found the endotoxin levels in the purified
13 MAB1843 to be < 0.1 EU/mL (Fig. 1C), indicating that certain amounts of MAB1843 are not
14 cytotoxic to DCs. Next, to test the physiological effect of MAB1843 on DC maturation, we
15 analyzed the expression of surface molecules and the secretion of cytokines in MAB1843- or
16 LPS-induced (positive control) DCs. MAB1843 enhanced the expression of surface
17 molecules such as CD80, CD86, and MHC class I and II (Fig. 2A), and promoted the
18 secretion of proinflammatory cytokines such as TNF- α , IL-1 β , and IL-6 (Fig. 2B), but His-
19 tagged protein itself did not affect to the production of cytokines in DCs (Supplementary
20 Figure 1). Whereas LPS stimulated the production of both IL-12p70 (involved in Th1
21 polarization) and IL-10 (involved in Th2 polarization), MAB1843 specifically induced the
22 secretion of IL-12p70 only (Fig. 2C), indicating that it may promote Th1 polarization.
23 Furthermore, MAB1843 suppressed the capacity of dextran and LPS to induce endocytosis in

1 DCs, indicating that it can functionally provoke the maturation of DCs towards promoting
2 Th1 polarization.

3 **MAB1843 Induces DC Maturation via TLR4 Signaling**

4 Toll-like receptors of immune cells, such as macrophages and DCs, act as initiators
5 of innate immunity by recognizing various pathogen-associated molecular patterns (PAMPs)
6 (23, 24). Apart from PAMPs, other *M. abscessus* antigens can activate DC maturation through
7 TLR2 or TLR4 (7, 8). Thus, we tested whether MAB1843 can modulate DC maturation
8 through TLRs as well. We analyzed the secretion of proinflammatory cytokines, such as
9 TNF- α and IL-6, in wild type (WT), TLR2 knockout (KO), and TLR4 KO DCs treated with
10 MAB1843, LPS (TLR4 agonist), Pam3CSK4 (TLR1/2 agonist), imiquimod (TLR7 agonist),
11 ODN1826 (TLR9 agonist), or Poly I:C (TLR3 agonist). Whereas the secretion of TNF- α and
12 IL-6 was observed in all three cell types stimulated by imiquimod, ODN1826, or Poly I:C,
13 both cytokines were completely inhibited in Pam3CSK4-stimulated TLR2 KO DCs and in
14 LPS-stimulated TLR4 KO DCs. The secretion of cytokines was completely blocked only in
15 TLR4 KO DCs stimulated by MAB1843 or LPS (Fig. 3A), indicating that MAB1843 can
16 modulate DC maturation through TLR4. As mitogen-activated protein kinases (MAPKs) and
17 nuclear factor-kappa B (NF- κ B) signaling are reportedly downstream mediators in TLR4
18 signaling (24), we investigated whether MAB1843 could enhance the activation of these two
19 mediators. We measured the phosphorylation of MAPKs and the expression of NF- κ B
20 inhibitor-alpha ($\text{I}\kappa\text{B}\alpha$) as an upstream molecule of NF- κ B in the cytosol. MAB1843
21 promoted the activation of MAPKs and NF- κ B in DCs derived from WT- and TLR2-
22 knockout mouse but not TLR4-knockout mouse (Fig. 3B and Supplementary Figure 2). In
23 addition, to investigate MAB1843 how to activate TLR4 signaling, we measured the
24 interaction between TLR4 and MAB1843 using the BLitz system (Supplementary Figure 3).

1 These results indicate that MAB1843 could induce the DC activation occurs through the
2 activation of TLR4-mediated MAPKs and NF- κ B signaling by direct binding with TLR4.

3 **MAB1843 Enhances CD4⁺ and CD8⁺ T Cell Proliferation Through DC Maturation**

4 Activated DCs mature during their migration to the lymph nodes. Once mature, they present
5 antigens to naïve T cells and induce T cell proliferation (12). To characterize the effect of
6 MAB1843 on DC and T cell interactions, we conducted a syngeneic mixed lymphocyte
7 reaction assay using OT-I T-cell receptor (TCR) transgenic CD8⁺ T cells and OT-II TCR
8 transgenic CD4⁺ T cells (25). The carboxyfluorescein succinimidyl ester (CFSE)-conjugated
9 ovalbumin (OVA)-specific CD8⁺ and CD4⁺ T cells were divided and co-cultured with DCs
10 presenting OVA₂₅₇₋₂₆₄ (Fig. 4A) or OVA₃₂₃₋₃₃₉ (Fig. 4B), which were effectively activated by
11 MAB1843 treatment and LPS stimulation. In addition, MAB1843 also potentiated the
12 production of IFN- γ by the activated CD4⁺ T cells, but not that of IL-4 (Fig. 4C). Considering
13 these results and the fact that MAB1843 stimulated the DC production of IL-12p70 (Fig. 1C),
14 we propose that this effect could be used in immunotherapy to polarize naïve CD4⁺ and CD8⁺
15 T cells towards an IFN- γ -producing Th1 phenotype.

1 DISCUSSION

2 Several strains of non-tuberculous mycobacteria, such as *Mycobacterium xenopi* and
3 *Mycobacterium kansasii*, have been known to cause pulmonary diseases (26, 27). Recent
4 research has shown that *M. abscessus* induces an immune response through TLR2 and dectin-
5 1 on host cells (7, 9), and MAB2560, the first purified antigen isolated from *M. abscessus*,
6 activates DCs via TLR4 (8). It is essential to understand the relationship between *M.*
7 *abscessus* and the immune system to develop a treatment strategy against infection by this
8 species. Therefore, it was necessary to complete the research on how the immune system
9 responds to *M. abscessus*-derived proteins. In this study, we investigated the effect of
10 MAB1843, another purified antigen isolated from *M. abscessus*, on the immune system.

11 Here, we report that MAB1843 plays a role as an adjuvant to induce the secretion of
12 proinflammatory cytokines and Th1 polarization via DC stimulation. Specifically, MAB1843
13 induced the maturation of DCs and the secretion of proinflammatory cytokines (viz., IL-
14 12p70, IL-1 β , IL-6, and TNF- α) via TLR4, both actions of which are important in T cell
15 activation.

16 It has been reported that the MAPK and NF- κ B pathways, activated by TLR
17 signaling, are involved in the maturation of DCs and the secretion of proinflammatory
18 cytokines (28, 29). In line with these studies, we found that MAB1843 induced the activation
19 of MAPKs and NF- κ B in DCs, which is important since DC maturation and proinflammatory
20 cytokine production play a key role in T cell polarization. Therefore, it is possible that
21 MAB1843 enhances the production of IL-12 in DCs through the activation of MAPKs and
22 NF- κ B, which in turn elicits the differentiation of CD4⁺ T cells into Th1 cells, which produce
23 IFN- γ . In line with these suggestions, we found that MAB1843 does indeed elicit Th1
24 polarization and IFN- γ production in Th1 cells. In this way, MAB1843 might be the link

1 between the innate immune response by DCs and the adaptive immune response by Th1 cells
2 to bacterial infection.

3 Our findings suggest that MAB1843 activates DCs and generates a Th1 response, as
4 well as induces Th1 polarization by enhancing IL-12 production in DCs and boosting IFN- γ
5 production in T cells. However, further *in vivo* studies are necessary to completely verify the
6 immune response to *M. abscessus*.

7 In conclusion, MAB1843 is a potent protein that induces DC maturation and Th1-
8 mediated immune response. Knowledge on the mechanism of how MAB1843 modulates the
9 activity of DCs could contribute to the development of vaccines against *M. abscessus*. The
10 identification of mycobacterial antigens that could be used as adjuvants to induce the
11 activation of APCs may direct the development of immunotherapy in the future.

12

1 MATERIALS AND METHODS

2 **Animals**

3 Female 4–6-week-old C57BL/6 (H-2K^b and I-A^b) mice were purchased from Orient Bio
4 (Daejeon, South Korea). TLR2 and TLR4 KO mice, as well as transgenic OT-I and OT-II
5 mice, were purchased from Jackson Laboratory (Bar Harbor, ME, USA). All of the animals
6 were housed in a specific pathogen-free facility and treated in accordance with the animal
7 care guidelines (Institutional Animal Care and Use Committee (IACUC) number: KU14046).

9 **Reagents and Antibodies**

10 Recombinant mouse granulocyte macrophage colony stimulating factor (rmGM-CSF) was
11 purchased from BioLegend (San Diego, CA, USA). The Annexin V/PI apoptosis detection kit
12 was purchased from BD Biosciences (East Rutherford, NJ, USA). Fluorescein isothiocyanate
13 (FITC)- or phycoerythrin (PE)-conjugated Abs—namely, FITC anti-mouse CD11c Abs
14 (Clone: N418), PE anti-mouse CD80 Abs (Clone: 16-10A1), PE anti-mouse CD86 Abs
15 (Clone: GL-1), PE anti-mouse H-2Kd/H-2Dd Abs (Clone: 34-1-2S), PE anti-mouse I-A/I-E
16 Abs (Clone: M5/114.15.2), FITC anti-mouse IFN- γ Abs (Clone: XMG1.2), and PE anti-
17 mouse IL-4 Abs (Clone: BVD4-1D11)—were purchased from BioLegend. TNF- α , IL-1 β , IL-
18 6, IL-10, and IL-12p70 ELISA kits were purchased from eBioscience (San Diego, CA, USA).
19 FITC-conjugated dextran was purchased from Sigma-Aldrich (St. Louis, MO, USA). The
20 TLR agonists (viz., LPS from *Escherichia coli* O111:B4, Pam3CSK4, imiquimod, Poly I:C,
21 and ODN1826) were purchased from Invivogen (San Diego, CA, USA). Antibodies against
22 phospho-ERK, phospho-p38, phospho-JNK, I κ B α , and β -actin were purchased from Santa

1 Cruz Biotechnology (Santa Cruz, CA, USA). CFSE was purchased from Life Technologies
2 (Eugene, OR, USA).

3 **Cloning of the *MAB1843* Gene**

4 The *MAB1843* gene was isolated from the full genome of *M. abscessus* for cloning into the *E.*
5 *coli* BL21 strain. *MAB1843* was amplified using a forward primer (5'-CATATG
6 ATGAAGCGTCTGATCCTCGGT-3') and a reverse primer (5'-AAGCTT
7 GTTGACGGGCGCGTTCAGGAA-3'). Thereafter, the PCR products were cleaved by NdeI
8 and HindIII, and the cleaved genes were then inserted into the pET-22b(+) vector (Novagen,
9 Madison, WI, USA).

10

11 **Purification of *MAB1843* from *E. coli* BL21**

12 The transformed *E. coli* BL21 was incubated in Luria-Bertani broth containing 100 µg/mL of
13 ampicillin. When the optical density at 600 nm reached 0.4–0.6, 1 mM of isopropylthio-β-D-
14 galactoside was added to the *E. coli* BL21 culture medium, which was then incubated for 6 h.
15 The *E. coli* BL21 cells were then harvested and lysed using lysozyme, dithiothreitol,
16 phenylmethanesulfonyl fluoride (PMSF), and DNase I. The supernatant was analyzed by
17 affinity chromatography with Ni-NTA agarose resin. The eluted solution was concentrated
18 and dialyzed against phosphate-buffered saline (PBS). Finally, endotoxins were removed by
19 polymyxin B-agarose (Sigma-Aldrich), and the endotoxin level was measured using the LAL
20 test kit (Lonza).

21

22 **Generation of Murine Bone Marrow Dendritic Cells**

23 DCs were collected from the bone marrow of the tibia and femora of C57BL/6 mice. The
24 progenitor cells were isolated from the bone marrow, and red blood cell lysis buffer was

1 added (Sigma-Aldrich). These cells were then mixed with RPMI 1640 medium containing 10%
2 fetal bovine serum, 1% penicillin/streptomycin, and GM-CSF. The cells were seeded into 12-
3 well cell culture plates and incubated at 37°C in a 5% CO₂ atmosphere. Fresh medium was
4 added on the third day. On the sixth day, the cells were further treated or harvested.

6 **Western Blot Analysis**

7 The harvested cells were washed with PBS and lysed using a lysis buffer (containing 0.5%
8 NP-40, 1 mM EDTA, 50 mM Tris-HCl (pH 8.0), 120 mM NaCl, 0.5 mM PMSF, 0.5 M NaF,
9 and 0.01% protease inhibitor cocktail (Biobasic, Amherst, NY, USA)). SDS-PAGE was
10 conducted using a 10% polyacrylamide gel, following which the protein bands were
11 transferred to a polyvinylidene difluoride membrane. After blocking the membrane with 5%
12 skimmed milk, primary Abs (anti-p-p38, anti-p-ERK, anti-p-JNK, anti-IκBα, and anti-β-actin)
13 were added to the membrane and incubation was carried out overnight at 4°C. On the next
14 day, after rinsing with Tris-buffered saline and Tween 20, the anti-mouse and anti-rabbit
15 secondary Abs were added to the membrane and a further incubation for 1 h at room
16 temperature (RT) was carried out. After rinsing the membrane, enhanced chemiluminescence
17 solution was added, and target bands were identified using the LAS-4000 imaging system
18 (Fuji Film, Tokyo, Japan). To enable interaction with other antibodies, stripping buffer
19 (Thermo Scientific, Waltham, MA, USA) was added to the membrane, following which the
20 blocking step was repeated, and new antibodies were added.

22 **Cytotoxicity Analysis**

1 MAB1843- or LPS-treated DCs were harvested and rinsed with PBS. Annexin V/PI staining
2 was performed on these cells for 15 min at RT. The cytotoxicity of MAB1843 on DCs was
3 analyzed by flow cytometry using the FACS Calibur instrument (BD Biosciences).

4 **Endocytosis Ability Analysis**

5 MAB1843- and LPS-treated DCs were treated with FITC-conjugated dextran and incubated
6 for 45 min at 37°C and 4°C, respectively. The DCs were then harvested and rinsed with PBS.
7 Thereafter, the DCs were stained using the PE-conjugated anti-CD11c Ab and analyzed by
8 flow cytometry.

10 **Mixed Lymphocyte Reaction (MLR)**

11 MAB1843- or LPS-treated DCs were incubated with OVA₂₅₇₋₂₆₄ or OVA₃₂₃₋₃₃₉. Then, 1×10^4
12 DCs and 1×10^5 CFSE-labeled T cells were co-cultured in a 96-well cell culture plate. These
13 transgenic OVA-specific CD8⁺ and CD4⁺ T cells were isolated from splenocytes of OT-I and
14 OT-II mice, respectively. After 96 h, the cells were harvested and rinsed with PBS. Then, the
15 cells were stained with Cy5 anti-CD8 or Cy5 anti-CD4 Abs and further analyzed by flow
16 cytometry.

18 **Intracellular Staining**

19 The harvested and rinsed cells were fixed in 4% paraformaldehyde and then permeabilized
20 using saponin buffer. The cells were stained with anti-IFN- γ and anti-IL-4 Abs for 20 min.

1 **Enzyme-Linked Immunosorbent Assay**

2 The levels of IL-12p70, IL-10, IL-1 β , TNF- α , IL-6, and IFN- γ were measured by ELISA
3 (eBioscience; R&D Systems, Minneapolis, MN, USA).

4 5 **Blitz assay**

6 The direct binding between rmTLR4/MD2 and MAB1843 was performed using the BLItz
7 system (ForteBio, Menlo Park, CA). Human rTLR4/MD2 tagged with anti-penta-His (HIS)
8 was purchased from R&D Systems (Minneapolis, MN). HIS biosensors (catalog no. 18-5078,
9 Fortebio) were hydrated for 10 min prior to the experiment. The concentration of HIS-tagged
10 rmTLR4/MD2 was 0.1 mg/ml, and that of purified MAB1843 was 0.1, 0.5, and 1 mg/mL and
11 BSA was 1 mg/mL. The setting was as follows: initial baseline for 30 s, loading for 300 s,
12 baseline for 60 s, association for 120 s, and dissociation for 120 s.

13 14 **Statistical analysis**

15 All experiments were repeated at least three times, with consistent results. Unless otherwise
16 stated, data are expressed as the mean \pm SEM. Variance analysis was used to compare
17 experimental groups with control values, whereas comparisons between multiple groups were
18 made using Tukey's multiple comparison tests (Prism 3.0; GraphPad software). A *P* value of
19 less than 0.05 was considered to indicate statistical significance.

20 21 **Conflict of interests**

22 All of the authors have no relevant conflict of interests.

23 24 **ACKNOWLEDGMENTS**

1 This study was supported by a National Research Foundation (NRF) of Korea grant, funded
2 by the Korean Government (NRF-2014R1A1A2054999 and NRF-2015R1A2A1A13001713),
3 and the Basic Research Laboratory Program through NRF Korea, funded by the Ministry of
4 Science, ICT & Future Planning (NRF-2013R1A4A1069575).

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

1 **REFERENCES**

- 2 1. Rolston KV, Jones PG, Fainstein V and Bodey GP (1985) Pulmonary disease caused
3 by rapidly growing mycobacteria in patients with cancer. *Chest* 87, 503-506
- 4 2. Set R and Shastri J (2011) Laboratory aspects of clinically significant rapidly growing
5 mycobacteria. *Indian J Med Microbiol* 29, 343-352
- 6 3. Jeon K, Kwon OJ, Lee NY et al. (2009) Antibiotic treatment of Mycobacterium
7 abscessus lung disease: a retrospective analysis of 65 patients. *Am J Respir Crit Care*
8 *Med* 180, 896-902
- 9 4. Lee MR, Sheng WH, Hung CC, Yu CJ, Lee LN and Hsueh PR (2015) Mycobacterium
10 abscessus Complex Infections in Humans. *Emerg Infect Dis* 21, 1638-1646
- 11 5. Maurer FP, Bruderer VL, Ritter C, Castelberg C, Bloemberg GV and Bottger EC
12 (2014) Lack of antimicrobial bactericidal activity in Mycobacterium abscessus.
13 *Antimicrob Agents Chemother* 58, 3828-3836
- 14 6. Nessar R, Cambau E, Reytrat JM, Murray A and Gicquel B (2012) Mycobacterium
15 abscessus: a new antibiotic nightmare. *J Antimicrob Chemother* 67, 810-818
- 16 7. Shin DM, Yang CS, Yuk JM et al. (2008) Mycobacterium abscessus activates the
17 macrophage innate immune response via a physical and functional interaction
18 between TLR2 and dectin-1. *Cell Microbiol* 10, 1608-1621
- 19 8. Lee SJ, Shin SJ, Lee SJ et al. (2014) Mycobacterium abscessus MAB2560 induces
20 maturation of dendritic cells via Toll-like receptor 4 and drives Th1 immune response.
21 *BMB Rep* 47, 512-517
- 22 9. Sampaio EP, Elloumi HZ, Zelazny A et al. (2008) Mycobacterium abscessus and M.
23 avium trigger Toll-like receptor 2 and distinct cytokine response in human cells. *Am J*
24 *Respir Cell Mol Biol* 39, 431-439

- 1 10. Haverkamp MH, van Dissel JT and Holland SM (2006) Human host genetic factors in
2 nontuberculous mycobacterial infection: lessons from single gene disorders affecting
3 innate and adaptive immunity and lessons from molecular defects in interferon-
4 gamma-dependent signaling. *Microbes Infect* 8, 1157-1166
- 5 11. Rottman M, Catherinot E, Hochedez P et al. (2007) Importance of T cells, gamma
6 interferon, and tumor necrosis factor in immune control of the rapid grower
7 *Mycobacterium abscessus* in C57BL/6 mice. *Infect Immun* 75, 5898-5907
- 8 12. Banchereau J and Steinman RM (1998) Dendritic cells and the control of immunity.
9 *Nature* 392, 245-252
- 10 13. Banchereau J and Palucka AK (2005) Dendritic cells as therapeutic vaccines against
11 cancer. *Nat Rev Immunol* 5, 296-306
- 12 14. Palucka K and Banchereau J (2012) Cancer immunotherapy via dendritic cells. *Nat*
13 *Rev Cancer* 12, 265-277
- 14 15. Schuler G, Schuler-Thurner B and Steinman RM (2003) The use of dendritic cells in
15 cancer immunotherapy. *Curr Opin Immunol* 15, 138-147
- 16 16. Bansal K, Elluru SR, Narayana Y et al. (2010) PE_PGRS antigens of *Mycobacterium*
17 *tuberculosis* induce maturation and activation of human dendritic cells. *J Immunol*
18 184, 3495-3504
- 19 17. Pecora ND, Gehring AJ, Canaday DH, Boom WH and Harding CV (2006)
20 *Mycobacterium tuberculosis* LprA is a lipoprotein agonist of TLR2 that regulates
21 innate immunity and APC function. *J Immunol* 177, 422-429
- 22 18. Heo DR, Shin SJ, Kim WS et al. (2011) *Mycobacterium tuberculosis* lpdC, Rv0462,
23 induces dendritic cell maturation and Th1 polarization. *Biochem Biophys Res*
24 *Commun* 411, 642-647

- 1 19. Lee SJ, Noh KT, Kang TH et al. (2014) The Mycobacterium avium subsp.
2 Paratuberculosis protein MAP1305 modulates dendritic cell-mediated T cell
3 proliferation through Toll-like receptor-4. *BMB Rep* 47, 115-120
- 4 20. Jung ID, Jeong SK, Lee CM et al. (2011) Enhanced efficacy of therapeutic cancer
5 vaccines produced by co-treatment with Mycobacterium tuberculosis heparin-binding
6 hemagglutinin, a novel TLR4 agonist. *Cancer Res* 71, 2858-2870
- 7 21. Jung ID, Shin SJ, Lee MG et al. (2014) Enhancement of tumor-specific T cell-
8 mediated immunity in dendritic cell-based vaccines by Mycobacterium tuberculosis
9 heat shock protein X. *J Immunol* 193, 1233-1245
- 10 22. Lee SJ, Shin SJ, Lee MH et al. (2014) A potential protein adjuvant derived from
11 Mycobacterium tuberculosis Rv0652 enhances dendritic cells-based tumor
12 immunotherapy. *PLoS One* 9, e104351
- 13 23. O'Neill LA, Golenbock D and Bowie AG (2013) The history of Toll-like receptors -
14 redefining innate immunity. *Nat Rev Immunol* 13, 453-460
- 15 24. van Duin D, Medzhitov R and Shaw AC (2006) Triggering TLR signaling in
16 vaccination. *Trends Immunol* 27, 49-55
- 17 25. Hogquist KA, Jameson SC, Heath WR, Howard JL, Bevan MJ and Carbone FR (1994)
18 T cell receptor antagonist peptides induce positive selection. *Cell* 76, 17-27
- 19 26. (1997) Diagnosis and treatment of disease caused by nontuberculous mycobacteria.
20 This official statement of the American Thoracic Society was approved by the Board
21 of Directors, March 1997. Medical Section of the American Lung Association. *Am J*
22 *Respir Crit Care Med* 156, S1-25
- 23 27. Marras TK and Daley CL (2002) Epidemiology of human pulmonary infection with
24 nontuberculous mycobacteria. *Clin Chest Med* 23, 553-567

- 1 28. Hayashi F, Smith KD, Ozinsky A et al. (2001) The innate immune response to
2 bacterial flagellin is mediated by Toll-like receptor 5. *Nature* 410, 1099-1103
- 3 29. Lee JS, Jung ID, Jeong YI et al. (2007) D-pinitol inhibits Th1 polarization via the
4 suppression of dendritic cells. *Int Immunopharmacol* 7, 791-804

1 **FIGURE LEGENDS**

2 **Fig. 1. Purification and cytotoxicity of recombinant MAB1843.** (A) Recombinant
3 MAB1843 was purified by affinity chromatography with Ni-NTA resin and then subjected to
4 SDS-PAGE and staining with Coomassie Brilliant Blue (left panel), as well as analysis by
5 western blotting using 1:1000 mouse anti-His tag antibodies (right panel). (B) Dendritic cells
6 were treated with the indicated concentrations of MAB1843 and LPS for 24 h and then
7 stained with Annexin V/PI. The results are representative of three independent experiments.
8 (C) Endotoxin levels in the purified MAB1843 were analyzed by the LAL endotoxin assay
9 kit.

10

11 **Fig. 2. MAB1843 induces the maturation of dendritic cells (DCs).** (A) Immature DCs
12 were cultured with 0.5 or 1 $\mu\text{g}/\text{mL}$ of MAB1843 or 50 ng/mL of LPS for 24 h and analyzed
13 for the expression of surface markers by two-color flow cytometry. DCs were stained with
14 FITC anti-CD11c antibodies and PE anti-CD80 antibodies, PE anti-CD86 antibodies, PE anti-
15 MHC class I antibodies, or PE anti-MHC class II antibodies. (B and C) Immature DCs were
16 cultured with 0.5 or 1 $\mu\text{g}/\text{mL}$ of MAB1843 or 50 ng/mL of LPS for 24 h. The amounts of
17 TNF- α , IL-1 β , IL-6, IL-12p70, and IL-10 in the culture medium were measured by ELISA.
18 The experiments were run at least in triplicates. * $P < 0.05$, ** $P < 0.01$, and *** $P < 0.001$,
19 when compared with DCs treated with MAB1843 only. (D) Mature DCs were generated by
20 stimulating the immature cells with 50 ng/mL of LPS or 0.5 or 1 $\mu\text{g}/\text{mL}$ of MAB1843 for 24
21 h. Endocytic activity at 37°C and at 4°C was assessed by flow cytometry, based on dextran-
22 FITC uptake. The percentages of dextran-FITC⁺ CD11c⁺ cells are indicated. The results are
23 representative of three independent experiments.


24

1 **Fig. 3. MAB1843 induces TLR4 signaling during dendritic cell (DC) maturation.** (A)
2 DCs derived from wild type (WT), TLR2 knockout (KO), and TLR4 KO mice were treated
3 with MAB1843 (1 $\mu\text{g}/\text{mL}$), LPS (50 ng/mL), Pam3CSK4 (Pam3) (10 $\mu\text{g}/\text{mL}$), imiquimod
4 (Imiq) (1 $\mu\text{g}/\text{mL}$), ODN1826 (ODN) (1 $\mu\text{g}/\text{mL}$), or Poly I:C (10 $\mu\text{g}/\text{mL}$) for 24 h. The
5 production of TNF- α and IL-6 in DCs was measured by ELISA. The experiments were run at
6 least in triplicates. *** $P < 0.001$. (B) DCs were treated with MAB1843 (1 $\mu\text{g}/\text{mL}$) or LPS (50
7 ng/mL) for 0, 5, 15, 30, and 60 min. Anti-p-p38 antibody, anti-p-ERK antibody, anti-p-JNK
8 antibody, anti-p38 antibody, anti-ERK antibody, anti-JNK antibody, anti-I κ B α antibody, and
9 anti- β -actin antibody was added to the western blot membrane. The results are representative
10 of three independent experiments.


11
12 **Fig. 4. MAB1843 induces T cell proliferation and Th1 polarization.** (A and B) Transgenic
13 OVA-specific CD8⁺ T cells and transgenic OVA-specific CD4⁺ T cells were isolated from
14 OT-I and OT-II mice, respectively. T cells were stained with carboxyfluorescein succinimidyl
15 ester and co-cultured for 96 h with DCs treated with 1 $\mu\text{g}/\text{mL}$ of MAB1843 or 50 ng/mL of
16 LPS. The cells were then analyzed by flow cytometry. (C) Transgenic OVA-specific CD4⁺ T
17 cells were co-cultured for 3 days with non-stimulated DCs, OVA₃₂₃₋₃₃₉-pulsed DCs, OVA₃₂₃₋
18 ₃₃₉-pulsed MAB1843-DCs, or OVA₃₂₃₋₃₃₉-pulsed LPS-treated DCs. The CD4⁺ T cell
19 expression of IFN- γ and IL-4 was detected by intracellular staining and flow cytometry. The
20 results are representative of three independent experiments.

Figure 1

A



B



C






Figure 2


A



B



C



D






Figure 4




Supplementary Figure 1




Supplementary Fig. 1. His-tagged protein of MAB1843 does not affect to the cytokine production in DCs. Immature DCs were cultured with 1 μg/mL of His-tag, MAB1843 or 50 ng/mL of LPS for 24 h. The amounts of TNF-α, IL-1β, and IL-6 in the culture medium were measured by ELISA. The experiments were run at least in triplicates. ****P* < 0.001. The results are representative of three independent experiments.

Supplementary Figure 2



Supplementary Fig. 2. MAB1843 induces the activation of IκB via TLR4 in DCs. DCs-derived from WT, TLR2 KO, and TLR4 KO mouse were treated with MAB1843 (1 μg/mL) for 0, 5, 30, and 60 min. Anti-IκBα antibody and anti-β-actin antibody was added to the western blot membrane. The results are representative of three independent experiments.

Supplementary Figure 3



Supplementary Fig. 3. Direct binding of MAB1843 to TLR4. Blitz assay to measure the binding of TLR4 to various doses of MAB1843 or PBS. The vertical and horizontal axes represent the light-shift distance (nm) in the solution and time (sec), respectively.